文献速递水电解质与酸碱

口服尿素治疗低钠血症校正速率的相关临床因素

Clinical factors associated with hyponatremia correction during treatment with oral urea.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

这项双中心回顾性研究纳入140例住院低钠血症患者的161次口服尿素治疗,发现年龄较大、基线血钠较低、累积尿素剂量较高及治疗最初48小时联合限水与血钠上升幅度更大独立相关,过度校正发生率3%。

要点

  • 年龄较大、基线血钠较低、累积尿素剂量较高与血钠上升幅度更大独立相关。
  • 治疗最初48小时内联合限水与血钠上升幅度更大相关,之后无此关联。
  • 过度校正发生率为3%,未观察到渗透性脱髓鞘综合征。

核心结论

  • 口服尿素治疗低钠血症时,年龄较大、累积剂量较高、基线血钠较低及初期限水与更快的校正速率相关。

研究设计与样本

  • 双中心回顾性研究,纳入140例住院低钠血症患者(血钠<135 mmol/L)的161次口服尿素治疗。

主要发现

  • 中位剂量30 g/天、持续4天(IQR 2-7天)使血钠从127升至134 mmol/L,47%的治疗事件低钠血症恢复正常。
  • 年龄较大(β 0.09,95% CI 0.02-0.16)、基线血钠较低(β -0.65,95% CI -0.78至-0.62)和累积尿素剂量较高(β 0.03,95% CI -0.02至-0.03)与血钠上升幅度更大独立相关。
  • 仅在治疗最初48小时内,联合限水与血钠上升幅度更大相关(β 1.81,95% CI 0.40-3.08)。
  • 过度校正发生5例(3%),未发现渗透性脱髓鞘综合征,因副作用停药11例(11%)。

临床怎么用

  • 临床可参考年龄、基线血钠、累积尿素剂量及初期是否限水来预判口服尿素校正速率,以实现逐步校正。

局限性

  • 回顾性设计,仅两家大学医院,样本量有限,结果需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oral urea is being used more commonly to treat hyponatremia, but factors contributing to the correction rate are unknown. We hypothesized that clinically relevant factors can be identified to help guide hyponatremia correction with oral urea. METHODS: This was a retrospective study in two university hospitals including hospitalized patients with hyponatremia (plasma sodium <135 mmol/L) treated with oral urea. Linear mixed-effects models were used to identify factors associated with hyponatremia correction. Rates of overcorrection, osmotic demyelination and treatment discontinuation were also assessed. RESULTS: We included 161 urea treatment episodes in 140 patients (median age 69 years, 46% females, 93% syndrome of inappropriate antidiuresis). Oral urea succeeded fluid restriction in 117 treatment episodes (73%), was combined with fluid restriction in 104 treatment episodes (65%) and was given as the only treatment in 27 treatment episodes (17%). A median dose of 30 g/day of urea for 4 days (interquartile range 2-7 days) increased plasma sodium from 127 to 134 mmol/L and normalized hyponatremia in 47% of treatment episodes. Older age (β 0.09, 95% CI 0.02-0.16), lower baseline plasma sodium (β -0.65, 95% CI -0.78 to -0.62) and higher cumulative urea dose (β 0.03, 95% CI -0.02 to -0.03) were independently associated with a greater rise in plasma sodium. Concurrent fluid restriction was associated with a greater rise in plasma sodium only during the first 48 h of treatment (β 1.81, 95% CI 0.40-3.08). Overcorrection occurred in 5 cases (3%), no cases of osmotic demyelination were identified and oral urea was discontinued in 11 cases (11%) due to side effects. CONCLUSION: During treatment with oral urea, older age, higher cumulative dose, lower baseline plasma sodium and initial fluid restriction are associated with a greater correction rate of hyponatremia. These factors may guide clinicians to achieve a gradual correction of hyponatremia with oral urea.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Pelouto A, Monnerat S, Refardt J, et al. Clinical factors associated with hyponatremia correction during treatment with oral urea. Nephrol Dial Transplant. 2025. PMID: 39013606. doi:10.1093/ndt/gfae164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。